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REVIEW ARTICLE
Mast Cell Regulation of the Immune Response
John J. Ryan, MD, Johanna K. Morales, MD, Yves T. Falanga, MD, Josephine F. A. Fernando, MD,
and Matthew R. Macey
Abstract: Mast cells are well known as principle effector cells of
type I hypersensitivity responses. Beyond this role in allergic dis-
ease, these cells are now appreciated as playing an important role in
many inflammatory conditions. This review summarizes the support
for mast cell involvement in resisting bacterial infection, exacerbat-
ing autoimmunity and atherosclerosis, and promoting cancer pro-
gression. A commonality in these conditions is the ability of mast
cells to elicit migration of many cell types, often through the
production of inflammatory cytokines such as tumor necrosis factor.
However, recent data also demonstrates that mast cells can suppress
the immune response through interleukin-10 production. The data
encourage those working in this field to expand their view of how
mast cells contribute to immune homeostasis.
Key Words: mast cells, mast cell regulation, immune response
(WAO Journal 2009; 2:224–232)
INTRODUCTION
Mast cells are highly regarded for their important roles inatopic diseases such as asthma, allergic rhinitis, and atopic
dermatitis. Their rapid activation by immunoglobulin E (IgE)
crosslinkage and subsequent release of inflammatory media-
tors has been the subject of several recent review articles.1–3
We are now appreciating that these cells have myriad func-
tions in the immune response. In keeping with the long-
standing theory that mast cells evolved as a means of protection
from parasitic infection, these cells seem to be quite impor-
tant as early sentinels of immune activation. However, this
only scratches the surface of how mast cells can modulate
inflammation. In fact, there is now compelling evidence that
mast cells alters innate and adaptive immunity in ways that
can either protect or damage the host. In this review, we will
discuss the latest findings implicating mast cells in responses
ranging from autoimmunity to cancer. Our goals are to reveal
the broad impact mast cells have on immune homeostasis and
to provide an update from the recent literature.
RESISTANCE TO BACTERIAL INFECTION
In 1996, 2 groups made an observation placing mast
cells squarely in the midst of bacterial immunity.4,5 Put
succinctly, mast cells are rapidly activated during bacterial
infection and produce a number of mediators eliciting both
innate and adaptive immunity. We now know that mast cells
express an array of innate immune receptors including members
of the Toll-like receptor (TLR) family and complement recep-
tors as reviewed by Sayed et al.6 The role of mast cell activation
in this process is currently being clarified and appears to be
nuanced in important ways that have therapeutic implications.
The greatest risk of bacterial infection remains sepsis,
with resulting shock and loss of organ perfusion that is life
threatening. Mouse models of bacterial infection have dem-
onstrated that an absence of mast cells greatly increases the
death rate because of septic peritonitis. The initial reasoning
for this was that mast cell activation by bacteria led to the
secretion of tumor necrosis factor (TNF), recruiting neutro-
phils to the site of infection.4,5 Although this certainly occurs,
there are several other factors involved that have only re-
cently been elucidated. The current thinking is that mast cell
activation leads to the rapid release of TNF and other factors
that blunt infection. In addition to eliciting neutrophil migra-
tion to the site of infection, mast cell-derived TNF evokes
dendritic cell trafficking to draining lymph nodes. The sub-
sequent activation of T-cells by dendritic cells results in the
necessary hyperplasia prompting a full and productive adap-
tive immune response. In the absence of mast cells or TNF,
lymph node hyperplasia is greatly diminished and mice are
much more susceptible to bacterial infection.7 However, mast
cell-derived interleukin (IL)-6 and the mast cell protease
(mMCP)-6 are also clearly important because loss of these
proteins also increases susceptibility to infection.8,9 Like
TNF, it appears that these enzymes are also involved in the
necessary recruitment of neutrophils to the site of infection.
Recent work has further demonstrated that MCPs can protect
the host from hypotensive shock by degrading the peptides
endothelin-1 and neurotensin.10–12 Therefore, it appears that
mast cells have a direct impact on immune responses to
bacteria and also modulate changes in the vasculature, pre-
venting pathologic responses to pathogens.
It is important to note that bacterial infection studies
have been carried out in mouse model systems. However, the
data are consistent in differing assay systems and in both the
gastrointestinal and pulmonary systems. The pathogens tested
include Escherichia coli, Staphylococcus aureus, Myco-
plasma pulmonis, Haemophilus influenzae, Klebsiella pneu-
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moniae, Citrobacter rodentium, Helicobacter felis, and Psu-
domonas aeruginosa.13 As such, the role of mast cells in
protection from bacterial infection appears quite important.
Mast Cells and Autoimmunity
In addition to their well-documented role in immediate
hypersensitivity (type I hypersensitivity responses), recent
studies have found mast cells functioning in the development
of autoimmune diseases classically termed types II–IV. A
consistent theme in these studies is the ability of mast cells to
elicit chemotaxis of other immune effector cells that sustain
the disease, reminiscent of the role mast cells play in asthma.
We will discuss each of these subtypes separately.
Type II Autoimmune Diseases
In bullous pemphigoid (BP) and Graves’ disease (GD),
the type I predilection of mast cells may contribute to the
progression of these type II autoimmune diseases. Mast cells
and IgE have been implicated in autoimmune pathology, able
to reproduce the early phase of BP lesion development in
human skin grafted to nu/nu mice.14,15 Indeed, human BP is
associated with elevated serum levels of IgE autoantibodies
and the presence of eosinophils in blisters, supporting a role
for IgE acting through mast cells in human BP.16,17
In the murine BP experimental model, mast cells have
been shown to play a key role in neutrophil recruitment. That
is, mast cell degranulation occurs within 60 minutes of
antibody transfer, causing neutrophilic infiltration and subse-
quent blistering of the skin.18 Mast cell-deficient mice or
wild-type mice treated with an inhibitor of mast cell degran-
ulation both fail to develop the disease.19 Local engraftment
of W/Wv mice with wild-type bone marrow mast cells (BM-
MCs) restores the BP phenotype, confirming the role for mast
cells.18 These authors postulate that mast cells triggered by
complement activation may be a crucial source of CXCL8, a
potent neutrophil chemoattractant.
Mast cells also play a role in GD ophthalmology, where
they infiltrate the orbital tissue of the eye and precede the
appearance of lymphocytes.20 Further, increased circulating
levels of stem cell factor (SCF) and IgE antibodies, some of
which are thyroid stimulating hormone receptor-specific, are
observed in a GD cohort.21 Mast cells are theorized to
function in GD ophthalmology as important sources of che-
moattractants (IL-16, CCL2), cytokines (IL-4, IL-5, IL-13),
and B cell costimulatory signals (CD154).22
Type III Autoimmune Diseases
Mast cells have been documented to function in type III
autoimmune diseases, including the Arthus reaction, systemic
lupus erythematosus (SLE), and rheumatoid arthritis (RA) as
reviewed by Sayed et al.6 Mast cells were first implicated in
a cutaneous Arthus response using W/Wv mice in 1991.
When compared with wild-type controls, mast cell-deficient
mice showed decreased edema, neutrophil infiltration, and
hemorrhage.23 Activation of the mast cell through FcRIII
and complement, resulting in TNF production and neutrophil
recruitment, was found to be important for this response.24–26
The role of mast cells in SLE is less clear. Previously,
Hiromura et al showed that mast cell infiltrates are present in
affected tissue from patients with SLE-mediated glomerulo-
nephritis, suggesting a mast cell influence.27 This theory was
supported by findings from Lyn kinase-deficient mice, which
develop lupus-like inflammation and demonstrate mast cell
hyperresponsiveness.28,29 However, a pristane-induced model
of SLE showed that mast cell-deficient W/Wv mice still
develop SLE symptoms that are equal or greater in magnitude
compared with wild-type littermates.30 This suggests that
mast cells have no role in SLE disease or may actually exert
a protective influence. It is important to note that SLE can
develop through several mechanisms that converge on a
similar destruction of joints, kidneys, and other organs. It
may be that the importance of mast cells varies with lupus
etiology.
In RA patients, the arthritic synovial tissue shows
increased mast cell numbers and includes mast cells that seem
to be degranulated.31 High levels of tryptase and histamine
have also been detected in the synovial fluid of some RA
patients and implicated in murine models.31,32 Mast cell-
deficient mice do not develop disease in an autoantibody
model of RA, whereas disease was restored when the mast
cell compartment was reconstituted.33 This seemed logical,
because mast cell-derived TNF has been implicated in disease
pathogenesis, and anti-TNF therapies are efficacious in hu-
man RA.34 The ability of some TNF-null mice to develop
arthritis after serum transfer suggests that other mediators are
required for RA disease progression, and that these mediators
may act in association with TNF. In support of this, mast cells
secrete IL-1 in the serum transfer model via FcRIII-medi-
ated activation, and IL-1 completely restores arthritic disease
in W/Wv mice.35,36 These findings offer new hope for treat-
ments targeting not only inflammatory cytokines, but mast
cells. For example, imatinib mesylate, which inhibits Kit-
mediated mast cell survival, effectively prevents collagen-
induced arthritis development and also treats established
disease.37 It is important to note that imatinib mesylate
suppresses BCR-Abl and other tyrosine kinases, and is there-
fore neither mast cell-specific nor free of side effects. How-
ever, this drug and others like it offer hope for progress in
suppressing mast cell responses.
Despite the logical nature of these findings, the impor-
tance of mast cells in RA has been recently debated. Work
from the laboratory of Howard Katz showed that mast cell-
deficient Wsh/Wsh mice develop arthritis similar to wild-type
littermates after anticollagen antibody injection.38 It appears
that W/Wv mice have a neutrophil deficiency that has been
underappreciated and that neutrophils rather than mast cells
may be the key determinant in at least this model of RA. As
with all animal models, translation to human patients remains
an important hurdle, but our fundamental understanding of
disease onset and progression is constantly evolving in ways
that will certainly provide patient benefit.
Type IV Autoimmune Diseases
Much work has been devoted to elucidating the mast
cell’s role in type IV autoimmune diseases, with the best-
described data related to multiple sclerosis (MS). Mast cells
have been shown to accumulate at sites of inflammatory
demyelination in the brain and spinal cord and are often
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found there in a degranulated state.39 Furthermore, high
levels of tryptase and histamine are often found in the
cerebrospinal fluid of MS patients, suggesting mast cell
activation.40,41 Gene-expression profiling has demonstrated
that transcripts encoding the histamine 1 (H1) receptor,
tryptase, and FcRI, are highly expressed in the central
nervous system (CNS) plaques of chronic MS patients.42
W/Wv mice display a very mild MS disease state and
show delayed onset when compared with their wild-type
littermates.43 Furthermore, the entry of CD4 and CD8
T-cells into the CNS also appears to be compromised in
W/Wv mice.44 Indeed, several aspects of the T-cell response
to myelin peptide in MOG35–55-induced experimental allergic
encephalomyelitis (EAE) seem to be defective in W/Wv mice.
Selective mast cell reconstitution of W/Wv mice through IV
transfer of BMMC restores severe disease susceptibility,44
strongly supporting a role for mast cells.
How mast cells promote EAE is a developing story. It
has been suggested that MCPs expressed in the CNS could
contribute to direct local tissue destruction. Their presence in
areas prone to autoimmune damage, including joints, the
CNS, and the pancreas, is consistent with this idea.45 How-
ever, mast cells may not exert their most potent effects on MS
from within the CNS. Tanzola et al suggest that mast cells act
outside the CNS, because mast cell reconstitution does not
appreciably repopulate the brain or spinal cord.46 Thus, the
current thinking is that mast cells promote MS by inducing
migration of inflammatory cells into the CNS. Gregory et al
showed that W/Wv mice exhibit 5- to 7-fold decreases in the
number of CD4 and CD8 T-cells that enter the CNS,
corresponding with reduced inflammation and demyelination
in the brain and spinal cord. Furthermore, CD8 T-cells
primed in mast cell-deficient mice express significantly de-
creased amounts of interferon (IFN) and CD44 post-MOG
immunization, despite normal T-cell development and com-
parable peripheral T-cell numbers in these W/Wv mice.44
These data fit the known role for mast cells in cell recruit-
ment. That is, mast cells are known to elicit migration of
many cell types, including myeloid dendritic cells and effec-
tor CD8 T-cells, through the release of factors including
LTB4 and TNF.47,48
These results suggest that mast cell-mediated effects on
T-cells may be paramount in type IV hypersensitivity. Oddly,
mast cell-derived IL-4, a TH2 cytokine, appears to be one of
the major players in the progression of MS, a TH1- and
Th17-associated disease. Mast cell-derived IL-4 is necessary for
severe disease progression and to produce an optimal TH1
response in MOG35–55-induced EAE.49 Yao et al explain this
paradox by showing that IL-4 promotes IL-12 expression
through the inhibition of IL-10 transcription in dendritic cells.50
How mast cells are activated in MS is being clarified.
Melissa Brown’s group has demonstrated that FcR-medi-
ated activation can be a critical component to EAE.51 How-
ever, it is also possible that complement receptors play a vital
role. Urich et al recently showed that EAE exacerbation by
injecting antimyelin oligodendrocyte protein antibodies was
dependent upon complement.52 Because mast cells express
several complement receptors, including C3aR, C5aR, CR2,
and CR4,53 activation by more than one pathway seems quite
plausible.
Collectively, these studies strongly suggest a role for
mast cells in MS elicitation. Many MS patients suffer from a
relapsing and remitting form of the disease. One wonders if
the numerous therapies used to combat the prototypical mast
cell-associated diseases, allergy, and asthma, might be effi-
cacious at least in lengthening remission. These could include
histamine- and leukotriene-targeted agents. LTB4 antagonism
has been used successfully in EAE models.54,55 The role of
histamine in MS is difficult to discern from the literature. For
example, the use of H1 antagonists appears to delay the onset
of multiple sclerosis symptoms,56 and suppressed EAE sever-
ity.57 Likewise, the H2 antagonist dimaprit inhibited EAE
pathology, including suppressing blood–brain barrier leak-
age.58 These data suggest that histamine may promote MS
pathology, perhaps because of its vascular effects. However,
histamine decarboxylase-deficient mice, which cannot make
histamine, have more severe EAE, indicating a protective role
for histamine. Related to this, loss of histamine H3 receptor
expression, which is normally confined to the nervous sys-
tem, also appears to exacerbate EAE.59 A unified view is that
histamine interactions with its H1 and H2 receptors promotes
inflammation and vascular leakage, whereas H3 interactions
in the CNS are protective.
Mast cells and inflammatory bowel disease
The role of mast cells in inflammatory bowel disease
(IBD) has been the focus of a recent review60 and will be
dealt with briefly here. IBD is often categorized into 2 major
subcategories: Crohn’s disease, which is largely classified as a
TH1 inflammatory condition, and ulcerative colitis, typically
classified as a TH2 condition. The evidence that mast cells
participate in IBD is logical but largely correlative. Mast cells
are found in the gut, particularly in the lamina propria and the
submucosa, located near blood vessels and nerve end-
ings.61–66 Their activation is known to elicit mucosal exuda-
tion, leukocyte recruitment, and interactions with the nervous
system.26,67–70 Therefore, mast cell involvement in IBD has
been strongly suspected, especially given that mast cell num-
bers and mediators are increased in the gastrointestinal tract
of IBD patients.63,71–74 Further data suggest that mast cells are
an important source of TNF in IBD, and that steroids or TNF
blocking antibodies can reduce IBD severity in part by
blocking mast cell-derived TNF.75–81
As described with clarity by Rijnierse and coworkers
(2007), there are discrepancies concerning the role of mast
cells in IBD when mouse models are employed. Two issues
need to be taken into account. First, some animal models
employ inflammatory substances such as 2,4,6-trinitroben-
zene sulfonic acid or Dextran sodium sulfate that are either
dissolved in ethanol-containing solutions or directly elicit
epithelial damage. These models have demonstrated disease
without evidence for a mast cell component. Secondly, some
experimental models have employed Ws/Ws rats that are
purportedly mast cell deficient. As discussed by Rijnierse and
coworkers, there is evidence that these animals in fact do
have mast cells in the colon, making it difficult to interpret
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data using Ws/Ws rats. These authors have recently devel-
oped a hapten-based model of colitis that does not occur in
mast cell-deficient W/Wv mice, and demonstrates a role for
mast cell-derived TNF in disease pathology.82 We look for-
ward to learning more about the role of mast cells in this
chronic inflammatory disease as relevant models progress.
An unexpected suppressive role for mast cells in
type IV hypersensitivity
Although mast cells are most often noted for their
inflammatory capacity, recent data suggest that they are not
monolithic. For example, Hagaman and coworkers showed
that human mast cells can secrete IL-1 receptor antagonist, a
plausible means of suppressing inflammation.83 Striking ev-
idence of mast cell-mediated immunosuppression comes
from recent work published by the laboratory of Stephen
Galli.84 In studying type IV hypersensitivity reactions to
poison oak and poison ivy, this group found that mast
cell-deficient mice (both W/Wv and Wsh/Wsh) exhibited
stronger responses than wild-type littermates to uroshiol, the
allergen-bearing sap derived from poison oak and poison ivy.
A normal inflammatory response was found when wild-type
mast cells were transplanted into mast cell-deficient mice.
Conversely, mice reconstituted with IL-10/ mast cells
showed increased epidermal ulceration and necrosis and der-
mal leukocytic infiltration compared with controls, showing
that mast cell-derived IL-10 is required for limiting inflam-
mation and edema associated with urushiol. Lastly, engraft-
ment with FcR/ BMMC, which lack expression of both
FcRI and FcRIII, failed to restore the suppressive effect,
indicating that mast cells are activated through Fc receptors in
this model 84. The ability of mast cells to limit inflammation,
through IL-10 secretion or other factors, creates a nuanced
picture of the mast cell response warranting reconsideration
in some cases.
Mast Cells and Cancer
The link between inflammation and cancer is a long-
standing observation now supported by substantial scientific
evidence. In fact, many cancers are associated with specific
inflammatory conditions. For example, colorectal cancer is
associated with IBD, Crohn’s disease, and chronic ulcerative
colitis. Pancreatic carcinoma is linked to chronic pancreatitis,
whereas lung carcinoma is associated with bronchitis.85 Ad-
ditionally, infectious agents causing chronic inflammation are
known to increase cancer incidence. Heliobacter pylori is the
world’s leading cause of gastric cancer. Similarly, Hepatitis B
and C viruses increase the incidence of hepatocellular carci-
noma.85,86 The fact that long term use of nonsteroidal anti-
inflammatory drugs, including cyclooxygenase (COX) inhib-
itors, greatly reduces the risk of colon cancer and breast
cancer illustrates the strong link between inflammation and
cancer is.85,87–90
If chronic inflammation promotes oncogenesis, the
mast cell is a logical participant in this process. Mast cells
potentiate inflammation by releasing mediators such as his-
tamine, leukotrienes, tryptase, and prostaglandins, which col-
lectively increase vascular permeability and promote leuko-
cyte migration. Mast cells also produce angiogenic and
inflammatory factors, including vascular endothelial growth
factor (VEGF), monocyte chemotactic protein-1 (MCP-1;
CCL2), MCP-2 (CCL8), monocyte inflammatory protein-1
(MIP-1; CCL3), IL-4, IL-13, IL-1, granulocyte macro-
phage colony stimulating factor (GM-CSF), granulocyte col-
ony stimulating factor (G-CSF), IFN-, and TNF.2,85,91
Please note that the set of cytokines produced varies with the
mast cell-activating stimulus, and the species studied. Impor-
tantly, significantly increased numbers of mast cells have
been found at the sites of many human and murine tumors,
including malignancies of the breast, pancreas, lung, and
stomach.92–96 Mast cell migration is most likely mediated by
SCF, which is secreted by many tumors and promotes mast
cell activation.2,97–99 Increased mast cell numbers have
also been observed in patients with chronic inflammatory
conditions known to promote cancer, including H. pylori
infection100 and IBD.72,101 Mouse experiments have shown
increased mast cell numbers associated with skin carcino-
genesis102,103 and chemically induced intestinal epithelial
tumors. Furthermore, tumor incidence was significantly de-
creased in mast cell-deficient c-kit mutant mice.104 Similarly,
mast cells are necessary for the initiation of adenomatous
polyps in the colons of mice predisposed for this condition,105
and for the expansion of pancreatic islet tumors resulting
from aberrant expression of the Myc transcription factor.106
It is plausible that mast cells promote tumor angiogen-
esis by secreting VEGF as part of an inflammatory cascade
(Fig. 1). Tryptase, secreted by activated mast cells, activates
the PAR-2 receptor, increasing COX activity.107–109 COX
activity prompts PGE2 production, which is known to elicit
VEGF production in mast cells.90,110 Human mast cells are
capable of secreting all 4 isoforms of VEGF-A, and VEGF-B,
VEGF-C, and VEGF-D.110,111 Mast cells have also been
shown to be pivotal in the angiogenesis of several murine
tumors.102,106 VEGF, also secreted by tumor cells, is known
to have a highly mitogenic effect on endothelial cells, thus
contributing to the neovascularization critical for tumor
growth and survival.111–113 It is noteworthy that mast cells
also express VEGFR1 and VEGFR2, making it possible for
tumors and mast cells to use VEGF in both autocrine and
paracrine manners.110 Another mediator of inflammation is
TNF, which effectively recruits neutrophils and macro-
phages. TNF has been shown to increase angiogenesis, tumor
growth, and metastasis.114 Like VEGF, TNF can also be
secreted by both mast cells and tumor cells.1,29,30 Therefore,
it is plausible that crosstalk between mast cells and tumor
cells creates a positive feedback loop exacerbating inflam-
mation, promoting malignant transformation and tumor pro-
gression.
A recent paper by Huang et al115 emphasized the
potential of mast cell involvement in tumor formation. This
group demonstrated that a wide array of tumor types secrete
SCF, which promotes mast cell recruitment to tumors in vivo.
Furthermore, the presence of mast cells in the tumor en-
hanced tumor growth and decreased host survival. Although
SCF is known to promote many activities in mast cells, an
interesting issue noted in this paper was SCF-induced secre-
tion of matrix metalloproteinase (MMP)-9 secretion. MMP-9
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furthers SCF production from tumors by cleaving surface-
bound SCF into a soluble molecule, facilitating a positive
feedback loop (Fig. 1). An important aspect of this work was
the indication that mast cells may promote immunosuppres-
sion at the tumor site, perhaps because of the increased
presence of regulatory T-cells. We found these data to be
particularly intriguing, because of our recent demonstration
that mast cells can cause regulatory T-cell migration.116
Collectively, this group and the work of others suggests that
mast cells may be a critical player in tumor progression,
promoting angiogenesis and immunosuppression. Certainly,
more work in this important area is warranted.
Mast Cells and Sclerosis
Systemic sclerosis
Sclerosis, the hardening of tissues, affects several dif-
ferent organs. There is evidence that mast cells can contribute
to sclerotic pathology. The role of mast cells in systemic
sclerosis (SSc) has been covered in 2 recent review arti-
cles,6,117 and will be dealt with only briefly here. SSc is
denoted by autoimmunity, inflammation, and vascular pathol-
ogy with progressive interstitial and perivascular fibrosis that
can affect the skin and many internal organs. The disease is
considered incurable and in its most severe form (diffuse
cutaneous SSc) has a mortality rate of 45% in 10
years.118,119 Mast cells are known to secrete TGF and
proteases that collectively promote sclerosis.120 A mouse
model employing so-called tight skin mice has demon-
strated an increase in mast cell density and degranula-
tion.121 This correlation is strengthened by data indicating
that mast cell stabilizers or chymase inhibition can im-
prove disease in these animals.122–124
Atherosclerosis
The development of atherosclerosis is caused by the
activation and dysfunction of endothelial cells. A local defect
in endothelial cell homeostasis promotes the adhesion of
leukocytes and activated platelets to the damaged endothe-
lium. This leads to increased vessel permeability that is
promoted by lipid components in the plasma, such as oxi-
dized low-density lipoprotein (oxLDL). Macrophages ex-
posed to oxLDL differentiate into foam cells.125 Foam cells
secrete a variety of substances involved in the early phases of
plaque development in the vessel intima, known as fatty
streaks. The development of fatty streaks is facilitated by
diverse leukocytes, including neutrophils, monocytes, mac-
rophages, basophils, B- and T-cells, dendritic cells, and mast
cells.125 These inflammatory cells promote an accumulation
of lipids via increased blood vessel permeability, enhancing
the maturation of fatty streaks into mature atherosclerotic
plaques. Plaques are covered by an inflammatory cap con-
taining macrophages, T-cells, and mast cells. Over time, the
growing plaque narrows the blood vessel lumen, resulting in
locally increased blood pressure upstream from this stenosis.
Eventually, the plaque can rupture. Release of tissue compo-
nents into the blood initiates the coagulation cascade and the
subsequent formation of a thrombus. The thrombus travels
through the blood vessel and can cause arterial occlusion,
resulting in complications such as pulmonary emboli, myo-
cardial infarction, or stroke.125,126
Several studies have demonstrated mast cell accumula-
tion in both human and mouse atherosclerotic plaques, per-
haps 6-fold greater than normal tissue.125–128 How mast cells
are activated in this condition remains unclear; a simple
explanation may be the increase in hydrostatic pressure at the
site of the plaque. Activated mast cells in the plaque can
contribute to atherosclerosis in several important ways. Their
cytokine and chemokine secretion, particularly TNF and
IL-6, promotes leukocyte infiltration. Furthermore, histamine
and lipid-derived factors can act as autacoids, regulating
vascular tone. Mast cells also produce proteases, which mod-
ify vascular permeability and remodeling. Particularly, serine
FIGURE 1. Positive feedback loops promoting mast cell-mediated angiogenesis in cancer. A wide variety of tumors are
known to secrete SCF, which induces mast cell migration in vivo. Mast cell activation by SCF induces MMP-9 production,
which clips membrane-bound SCF from the tumor cell surface, increasing the bioavailability of SCF. Activated mast cells pro-
duce tryptase, which can enhance tumor cell COX activity via the PAR-2 receptor. COX-mediated PGE-2 production can acti-
vate mast cells to secrete VEGF, promoting tumor angiogenesis.
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proteases derived from mast cells, such as chymase and
tryptase, can activate MMPs locally, causing plaque instabil-
ity because of decreased thickness.129 Mast cells are likely
contributors to plaque neovascularization, which initially pro-
motes tissue survival. However, these vessels are fragile, and
their rupture can facilitate plaque release.130
Recent advances in this area include work from the
laboratory of Guo-Ping Shi.131 This group used an athero-
sclerosis-prone LDL receptor-deficient mouse to demonstrate
that mast cell deficiency (via crossing to Wsh mice) reduces
lesion size, clinical score, lipid content, and the number of
T-cells and macrophages present. They also noted an increase
in collagen content and cap size, which could stabilize the
plaque. Using mast cell reconstitution, this group further
demonstrated that IL-6- or IFN-deficient mast cells did not
restore atherogenesis like wild-type mast cells, suggesting
that mast cell-derived IL-6 or IFN enhances plaque forma-
tion. An interesting aspect of these studies was that TNF-
deficient mast cells did restore atherogenesis, suggesting that
mast cell-derived TNF was not essential to this process. The
authors further showed that proinflammatory cytokines such
as IL-6 are likely acting to increase the expression of cysteine
protease cathepsins, which degrade the connective tissue
matrix and promote atherogenesis.
CONCLUSIONS
Mast cells are now appreciated as a type of frontline
sentinel, activated by numerous stimuli and employed to
protect the host in a variety of situations (Fig. 2). This role in
innate immunity is augmented by their ability to interact with
and alter the adaptive immune response. Unfortunately, the
mast cell response can be pathologic as well. Although a
number of mast cell activities warrant focus, a recurring
theme is their ability to secrete chemoattractants such as
TNF, IL-6, leukotrienes, and some proteases. These factors,
working together with the vasodilatory effects of histamine,
prompt cellular movements toward target organs, even to
tissues where the activated mast cell is not located. An
interesting and new aspect of mast cell biology is their
apparent ability to provide immunosuppression. Although
IL-10 production is a logical mechanism for this function, the
role of proteases in degrading venoms and regulating shock,
and the unidentified factor(s) promoting regulatory T-cell
migration, seem to be important. A wonderful aspect of the
long history of mast cell-associated atopic disease is our
possession of efficacious clinical tools targeting mast cell
function. We look forward to learning how these tools can be
employed in nonatopic conditions where mast cells have a
role.
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